Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD)
NCT ID: NCT01472939
Last Updated: 2021-06-09
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
480 participants
INTERVENTIONAL
2012-02-27
2013-05-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy And Safety Of PF-00885706 For The Relief Of Symptoms In Subjects With Gastro-esophageal Reflux Disease (GERD)
NCT00730665
PPI Versus Placebo in Severe Functional Heartburn
NCT00222989
Validation of Patient-reported Outcomes Measures for the Assessment of Gastroesophageal Reflux Disease (GERD) Symptoms
NCT00703534
Symptom Improvements in Gastroesophageal Reflux Disease (GERD) Patients
NCT00394472
Physiology of GERD and Treatment Response
NCT04292470
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SSP-002358 (0.1 mg) + Proton Pump Inhibitor (PPI)
SSP-002358 (0.1 mg) + PPI
0.1 mg tablet three times daily (t.i.d.) taken in addition to a PPI
SSP-002358 (0.5 mg) + PPI
SSP-002358 (0.5 mg) + PPI
0.5 mg tablet t.i.d. taken in addition to a PPI
SSP-002358 (2.0 mg) + PPI
SSP-002358 (2.0 mg) + PPI
2.0 mg tablet t.i.d. taken in addition to a PPI
Placebo + PPI
Placebo + PPI
Placebo t.i.d. taken in addition to a PPI
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SSP-002358 (0.1 mg) + PPI
0.1 mg tablet three times daily (t.i.d.) taken in addition to a PPI
SSP-002358 (0.5 mg) + PPI
0.5 mg tablet t.i.d. taken in addition to a PPI
SSP-002358 (2.0 mg) + PPI
2.0 mg tablet t.i.d. taken in addition to a PPI
Placebo + PPI
Placebo t.i.d. taken in addition to a PPI
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Aged between 18 and 70 years, inclusive.
3. Subjects with a history of the cardinal symptoms of GERD (both heartburn and regurgitation) prior to PPI therapy.
4. Subjects with symptoms of GERD for at least 6 months prior to the Screening Visit.
5. Subjects who have persistent symptoms of regurgitation for 3 or more days over the past week with or without heartburn while on PPI.
6. Subjects have at least some improvement to the symptom of heartburn while on PPI therapy.
7. Subjects on PPI therapy for at least 8 weeks prior to the Screening Visit of which the last 4 weeks are on a stable labeled dose for any GERD indication according to the country label, where a change of PPI therapy would not impact the symptoms (twice-daily dosing of PPI is not allowed in the last 4 weeks)
Exclusion Criteria
2. Subjects with dyspepsia symptoms that are more predominant than their GERD symptoms (heartburn and/or regurgitation).
3. Subjects with prior endoscopic anti-reflux procedure or major GI surgery or subjects with major GI disorders.
4. Presence of severe and clinically uncontrolled cardiovascular, liver, lung or neurologic disease, cancer or AIDS.
5. Alarm symptoms suggestive of malignancies or organic disease.
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shire
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Study Director
Role: STUDY_DIRECTOR
Takeda
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
HOPE Research Institute
Phoenix, Arizona, United States
Genova Clinical Research
Tucson, Arizona, United States
Lynn Institute of the Ozarks
Little Rock, Arkansas, United States
Preferred Research Partners, Inc
Little Rock, Arkansas, United States
Arkansas Gastroenterology
North Little Rock, Arkansas, United States
Anaheim Clinical Trials
Anaheim, California, United States
Southern California Research Institute Medical Group Inc
Los Angeles, California, United States
Medical Center for Clinical Research
San Diego, California, United States
Clinicos
Colorado Springs, Colorado, United States
Connecticut Gastroenterology Institute
Bristol, Connecticut, United States
Stamford Therapeutics Consortium
Stamford, Connecticut, United States
Medical Research Unlimited, LLC
Aventura, Florida, United States
Consultants for Clinical Research of South Florida
Boynton Beach, Florida, United States
PAB Clinical Research
Brandon, Florida, United States
Avail Clinical Research, LLC
DeLand, Florida, United States
S & W Clinical Research
Fort Lauderdale, Florida, United States
Medical Research Unlimited, LLC
Hialeah, Florida, United States
Jupiter Research
Jupiter, Florida, United States
Pines Clinical Research, Inc.
Pembroke Pines, Florida, United States
Radiant Research
Pinellas Park, Florida, United States
Accord Clinical Research, LLC
Port Orange, Florida, United States
Meridien Research
St. Petersburg, Florida, United States
Gastrointestinal Specialists of GA, PC
Marietta, Georgia, United States
Digestive Research Associates
Newnan, Georgia, United States
Rockford Gastroenterology Associates, Ltd
Rockford, Illinois, United States
Professional Research Network of Kansas, LLC
Wichita, Kansas, United States
Research Integrity
Owensboro, Kentucky, United States
Clinical Trials Management
Metairie, Louisiana, United States
Louisiana Research Center, LLC
Shreveport, Louisiana, United States
Meritus Medical Center
Hagerstown, Maryland, United States
Beacon Clinical Research
Brockton, Massachusetts, United States
Center for Digestive and Liver Diseases
Mexico, Missouri, United States
Clinical Research Group of Montana
Bozeman, Montana, United States
Meridian Clinical Research
Omaha, Nebraska, United States
Clinical Research Center of Nevada
Las Vegas, Nevada, United States
New Jersey Physicians, LLC
Clifton, New Jersey, United States
UNC Hospitals
Chapel Hill, North Carolina, United States
Carolinas Research Associates
Davidson, North Carolina, United States
Cumberland Research Associates
Fayetteville, North Carolina, United States
Vital Research, Inc.
Greensboro, North Carolina, United States
Carolinas Research Associates
Harrisburg, North Carolina, United States
Peters Medical Research
High Point, North Carolina, United States
Wake Research Associates
Raleigh, North Carolina, United States
Prestige Clinical Research
Franklin, Ohio, United States
Oklahoma Foundation for Digestive Research Sciences Center
Oklahoma City, Oklahoma, United States
Family Medical Associates
Levittown, Pennsylvania, United States
Guthrie Clinic, Ltd.
Sayre, Pennsylvania, United States
Omega Medical Research
Warwick, Rhode Island, United States
Meridian Clinical Research
Dakota Dunes, South Dakota, United States
Clinsearch, LLC
Chattanooga, Tennessee, United States
Radiant Research Dallas-North
Dallas, Texas, United States
GI Consultants, P.A.
Houston, Texas, United States
Pasadena Gastroenterology Assoc, dba Digestive Health Center
Pasadena, Texas, United States
Office Based Practitioner
San Antonio, Texas, United States
Advanced Research Institute
Clinton, Utah, United States
Advanced Research Institute
Logan, Utah, United States
Advanced Research Institute
Ogden, Utah, United States
Advanced Research Institute
Sandy City, Utah, United States
New River Valley Research Institute
Christiansburg, Virginia, United States
Blue Ridge Medical Center
Lynchburg, Virginia, United States
Ramstad Medical Associates
Suffolk, Virginia, United States
Aurora Wilkinson Medical Clinic
Summit, Wisconsin, United States
Hepato-Gastroenterology HK s.r.o.
Hradec Králové, , Czechia
Nemocnice Valasske Mezirici a.s.
Valašské Meziříčí, , Czechia
Praxis Dr. Andreas Schwittay-Facharzt fuer Innere Medizin
Böhlen, , Germany
Zentrum fur Innere Medizin, Klinikum Garmisch Partenkirchen
Garmisch-Partenkirchen, , Germany
Haus der Gesundheit
Ludwigshafen, , Germany
Praxis für Gastroenterologie und fachärztliche Innere Medizin
Ludwigshafen, , Germany
Medizinische Fakultät der Otto-von-Guericke Universität
Magdeburg, , Germany
Gemeinschaftspraxis Dres. Brandt
Potsdam, , Germany
Gemeinschaftspraxis Dres Josef und Wilma Großkopf
Wallerfing, , Germany
Daugavpils Regional Hospital
Daugavpils, , Latvia
Pauls Stradins Clinical University Hospital
Riga, , Latvia
Digestive Disease Centre "Gastro"
Riga, , Latvia
Vidzemes Hospital
Valmiera, , Latvia
NZOZ Specjalistyczne Centrum Gastrologii Gastromed
Bialystok, , Poland
Centrum Medyczne im Swietego Lukasza Sp. z o.o.
Częstochowa, , Poland
NZOZ ''Salvia''
Katowice, , Poland
Centrum Medyczne Szpital sw. Rodziny Sp. z o.o.
Lodz, , Poland
Gastromed Sp. K. NZOZ
Lublin, , Poland
Endoskopia Sp. z o.o.
Sopot, , Poland
NZOZ Vivamed
Warsaw, , Poland
Lexmedica
Wroclaw, , Poland
Aktywne Centrum Zdrowia NZOZ ZAWIDAWIE Sp. z o.o.
Wroclaw, , Poland
Brasov County Hospital
Brasov, , Romania
Centrul Medical Galenus
Târgu Mureş, , Romania
Cabinet Particular Policlinic Algomed SRL
Timișoara, , Romania
Policlinica "Dr. Citu" SRL
Timișoara, , Romania
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Shaheen NJ, Adler J, Dedrie S, Johnson D, Malfertheiner P, Miner P, Meulemans A, Poole L, Tack J, Thielemans L, Troy S, Vakil N, Zerbib F, Ruth M. Randomised clinical trial: the 5-HT4 agonist revexepride in patients with gastro-oesophageal reflux disease who have persistent symptoms despite PPI therapy. Aliment Pharmacol Ther. 2015 Apr;41(7):649-61. doi: 10.1111/apt.13115. Epub 2015 Feb 19.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2011-004388-62
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
SPD557-206
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.